Printer Friendly

Genetic polymorphism of GSTM1 and GSTP1 in lung cancer in Egypt.


Lung cancer (LC) is the leading cause of cancer-related malignancy worldwide, accounting for one-third of all cancer-related deaths worldwide, approximately 1.2 million new cases per year [1]. Despite the fact that the cause of most lung cancer is well known, the disease has proven difficult to diagnose early and treat successfully, reflecting limited advances in our understanding of the molecular mechanisms underlying lung carcinogenesis and individual susceptibility to lung cancer [2].

Tobacco smoke is the major risk factor for lung cancer development (90% of cases diagnosed). However, not all populations are equally susceptible to tobacco-related carcinogens [3]. Exposure to other environmental respiratory carcinogens, such as asbestos, benzene, coal tar, and other industrial chemicals may interact with tobacco smoke to increase risk. Thus, the identification of genes responsible for lung carcinogenesis susceptibility may allow us to perform screening programs and chemoprevention trials in subgroups of heavy smokers [4].

A family of enzymes, the glutathione-S-transferases (GSTs), has the general function of conjugating glutathione with electrophilic substances that are capable of generating free radicals, thus leading to detoxification of their effects. Genetic polymorphisms associated with reduced activity of GSTs are therefore of interest in the study of disease susceptibility [5].

The cytosolic isoenzymes of GST are divided into at least five major classes ([alpha], [mu], [pi], [theta], [zeta]) among which polymorphism have been detected in the genes encoding for GSTA1 (a class) GSTM1 ([mu] class), GSTP1 ([pi] class), CSTT1 ([theta] class) and GSTZ1 ([zeta] class) [6]. Among them the GSTM1, GSTP1 and GSTT1 genotypes have been extensively studied during recent years for their potential modulating role in individual susceptibility to environmentally-induced diseases, including cancer [7]. The GSTM1 gene on chromosome 1p13, according to the three alleles, can be grouped into two classes: GSTM1-null homozygote for the null allele (GSTM1-0), nonfunctional class and GSTM1-1 with at least one of the GSTM1a or GSTM1b alleles, functional class [8]. GSTM1-null was reported to be associated in some studies with increased susceptibility to inflammatory pathologies and increased risk of smoking related cancers [9]. The GSTM1 null polymorphism, are known to abolish enzymes activity. Individuals with GSTM1 null genotype have been reported to have higher levels of polycyclic aromatic hydrocarbon-dGMP adducts in lung tissues, which can induce genetic mutations [10].

The GSTP1 gene has been mapped to a small region of chromosome 11q [11]. GSTP1 is known to metabolize many carcinogenic compounds, among them benzo[a]pyrene diolepoxide (BPDE), which is one of the most important carcinogenic metabolites derived from tobacco smoke [12]. Given that GSTP1 is the most abundant GST isoform in the lung, it is anticipated to be of particular importance in the detoxification of inhaled carcinogens [4].

GSTP1 has two common non-synonymous single-nucleotide polymorphisms (SNPs) that result in [Ile.sup.105]Val and [Ala.sup.114]Val alterations in encoded amino acid sequence. At least two different alleles, GSTP1A and GSTP1B, have been identified encoding for GSTP1, exhibiting [A.sup.313]G base change in the latter allele which results in an [Ile.sup.105]Val amino acid replacement within the active site of the enzyme [13].

The [Val.sup.105] substitution results in steric restriction of the H-site due to shifts in the side chains of several amino acids. Thus, the [Val.sup.105] variant allozyme may be able to accommodate less bulky substrates than the [Ile.sup.105] allozyme and, as a result, may display substrate specificities that differ from those of the wild-type (WT) allozyme [14]. In addition, the thermal stability of the codon 105 variant allozyme differs from that of the WT [15]. These characteristics may be responsible, in part, for the reported association between this allozyme and carcinogenesis or variation in response to antineoplastic drugs [16].

Individual differences in the susceptibility to carcinogens play an essential role in the development of sporadic cancer. The biochemical basis for the genetic susceptibility to environmental hazards is related to genetic polymorphisms that normally occur in the general population, and involves a series of genes implicated in the metabolic activation or detoxification of environmental toxins [17].

In this study we investigate the role of GST isoenzymes polymorphism (GSTM1 and GSTP1), in lung cancer risk in Egyptian patients, considering age, gender, histopathological diagnosis and history of tobacco exposure.

Subjects and methods

Study subjects

The study population included 48 patients with lung cancer seen at bronchoscopy unit in National Cancer Institute, Cairo, Egypt. Cases were diagnosed as primary lung cancer by histological evaluation of tumor biopsies. Age, sex, self smoking, type of cancer and its grade were recorded. The control group consisted of 42 volunteers, none of them had lung cancer or any type of cancer and the same data were recorded for them.

Trans-nasal fiberoptic bronchoscopy was performed using an Olympus flexible fiberoptic bronchoscope, following the guidelines of the national institutes of health. Premedication included atropine (0.5 mg-IM) administrated 30 minutes before the procedure, with local upper airways anesthesia with 5 ml of 2% lidocaine. Multiple biopsies were obtained from the tumor mass seen and sent for histopathology.

Blood samples and DNA extraction

Blood samples of 5 ml were obtained from all subjects and collected in sterile tubes containing EDTA. Immediately after collection, whole blood was stored at -20[degrees]C until use. Genomic DNA was extracted from whole blood using the established protocol for DNA extraction from nucleated blood cells [18].

Analysis of GSTM1 polymorphism

The genetic polymorphism analyses for the GSTM1 gene was determined by the multiplex polymerase chain reaction (PCR) using the previously described method [19]. The appropriate fragment of the GST gene for GSTM1 was amplified with specific primers from human genomic DNA. The CYP2E1 gene was co-amplified as an internal positive control. The following primers were used in PCR reaction: GSTM1 primers of (sense) 5-GAACTCCCTGAAAAGCTAAAGC-3 and (antisense) 5-GTTGGGCTCAAATATACGGTGG-3, and CYP2E1 (sense) 5-TTGGTTGACTCACTCTTTCCTTT-3 and (antisense) 5-CCATCGTTTCAAAGGCTGAT-3. PCR was performed in a total volume of 25 [micro]l containing 200 ng genomic DNA, 5 [rho]M of each primer, 2.5 mM deoxyribonucleoside triphosphates (dNTPs), 1.5 mM Mg[Cl.sub.2], and 1 U thermostable Taq DNA polymerase using Little Genius, Bioer PCR system (Bioer Technology Co., U.S.A.). The amplification conditions were initial denaturation at 94[degrees]C for 5 min followed by 35 cycles of denaturation at 94[degrees]C for 30 sec, annealing at 54[degrees]C for 30 sec, extension at 72[degrees]C for 1 min, and final extension at 72[degrees]C for 10 min. The products of the PCR amplification (GSTM1:219 bp, CYP2E1: 495 bp) were separated electrophoretically on an ethidium bromide stained 2% agarose gel. The absence of amplified GSTM1 product (in the presence of control PCR product) indicated the respective null genotype.

Determination of the GSTP1 genotype

Each PCR reaction mixture (25 [micro]l) contained 5 [rho]M of each primer sense (5-ACCCCAGGG CTCTATGGGAA-3) and antisense (5-TGA GGG CAC AAG AAG CCC CT-3), 200 ng of genomic DNA, 1.5mM Mg[Cl.sub.2], 2.5mM each dNTPs and 1 U Taq polymerase (Biron Technologies). Amplification was performed with an initial denaturation at 94[degrees]C for 5 min followed by 35 cycles at 94[degrees]C for 30 sec, 56 [degrees]C for 30 sec, 72[degrees]C for 1 min, and final extension at 72[degrees]C for 10 min. After the confirmation of an amplified fragment of the expected size (176 bp) on an agarose gel, the PCR products were digested with 5 U of restriction enzyme BsmAI (New England BioLabs, UK) at 55 [degrees]C for one hour. DNA fragments were applied to electrophoresis through a 2% agarose gel and stained with ethidium bromide.

Electrophoresis of the digested PCR products showed individuals homozygous (ile/ile) for the GSTP1 BsmAI polymorphism as one band of 176 bp. Heterozygous (ile/val, val/val) for the polymorphism resulted in three bands of 176, 91 and 85. Homozygotes (val/val) showed two bands of 91 and 85 bp (which appear as one band due to close molecular size).

Statistical analysis

The Statistical Program SPSS for windows version 11 had been used in data entry and analysis. Descriptive and analytic statistics were done. Statistical significance was determined at the 95 percent confidence interval level. The lowest accepted level of significance was 0.05 or less. Risk ratios were estimated by odds ratios (OR).

The descriptive analysis was performed to compare observed and expected genotype frequencies using a chi-square test. We estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between lung cancer and genetic polymorphism using logistic regression models. The lung cancer cases were separately compared to the controls using multi-category logistic models.


For the demographic characteristics of the subjects, data from the control population (healthy Egyptian blood donors) and the LC patients were statistically analyzed. LC patients showed to be slightly older than controls. The mean age of the cases was 58.6 while it was 57.8 in control.

The number of male and female among cases was 32 and 16, respectively. Males were over-represented when compared to females (66.7% versus 33.3 %) showing that cases of lung cancer was significantly higher in males (p = 0.001). The frequency of smokers was higher in patients with LC than in controls (68.7% versus 33.3 %; p < 0.001) and among LC patients smokers was higher in male than females.

Among cases squamous cell carcinoma was the most hisological finding (68.75 %) followed by adenocarcinoma (18.75%) then small cell carcinoma (12.5 %), generally non-small cell lung cancer (NSCLC) is more frequent than small cell lung cancer (SCLC) and the most frequent stages were III and IV (64.6 %). Lung cancer patients compared to control group showed high distribution in old age, male and smokers (table 1).

GSTM1 gene polymorphism

The internal standard fragment amplified from GSTM1 was 219 bp. The absence of amplified product and the presence of control fragment were consistent with the null genotype (Fig. 1) The proportion of control individuals with GSTM1 null mutation was 33.3 % while in lung cancer cases it was 31.3 %. No significant differences were found between them (p = 0.8) (table 1) indicating that GSTM1 null mutation did not increase the risk of lung cancer incidence (odds ratio (OR) = 0.5, 95% confidence interval (CI) = (0.1-2.01), p-value = 0.33) (table 2).

GSTP1 gene polymorphism

The PCR product with G allele was digested to two fragments, whereas the PCR product with A allele remained undigested (Fig. 2). The frequency of GSTP1 ile/ile genotype was 18.7 % in patients and 66.6 % in control while the frequency of GSTP1 ile/val and val/val were 81.3 % in case of cancer and 33.4 % in control showing highly significant difference (table 1) in these polymorphism (p = 0.0001). Separately ile/val frequency was 64.6 % in cases versus 16.7 % in control (p= 0.001) while the ratio of val/val was 16.7 % in LC and 16.7 % in control.

Using the GSTP1 homozygous (ile/ile) as references group, the OR of GSTP1 heterozygous (ile/val) was 3.5 (95% CI= 1.01-12.5, P = 0.042) and the GSTP1 homozygous (val/val) was 0.4 (95% CI= 0.2-0.8, P= 0.27) indicating that GSTP1 mutant type (ile/val) represents high risk polymorphism for lung cancer (table 2).

For the association of combined gene polymorphisms with LC risk. We studied the risk of LC associated with the combination of the GSTM1 null, GSTP1 Ile/Val plus Val/Val.

A statistically significant association was observed (table 2) between the combination of GSTM1 and GSTP1 and overall lung cancer, (OR= 5.06, 95% CI= 1.3-20.2, P= 0.02).

When the risks associated with GST genotypes for lung cancer were considered in relation to smoking habits, smokers with GSTM1-positive genotype (table 3) were at an approximately 2.9-fold higher risk of lung cancer than non-smokers with GSTM1-positive genotype (95% CI, 1.2-6.8) and it was more in case of smokers with GSTM1-null genotype (OR=5.8, 95% CI: 0.7-50.7).

In the evaluation of the effect of interaction of GSTP1 gene and smoking on lung cancer risk, we used GSTP1 ile/ile genotype as a reference. It was found that non-smokers with GSTP1 abnormal genotype (table 4) were at an approximately 2.3-fold higher risk of lung cancer than nonsmokers with GSTP1 ile/ile genotype (OR=2.3, 95% CI: 0.8-6.3). While smokers with GSTP1 abnormal genotype were 5-fold high risk of lung cancer (OR= 5, 95% CI=1.8-13.4).


Inter-individual variability in glutathione-S-transferase (GST) enzyme activity can influence the susceptibility to cancers, especially in those with environmental determinants, such as lung cancer [20].

Nelson et al. [21] reported that the null genotype of GSTT1 was present in 64% of Chinese, 60% of Koreans, 28% of Caucasians and in 22% of African-Americans. This null genotype is more common in the Asians than Caucasians, strengthening the idea that polymorphisms in enzymes that metabolize tobacco carcinogens have a strong ethnical link. To our knowledge this is the first time to investigate the correlation between genetic polymorphism of GSTM1 and GSTP1 and lung cancer in Egyptian patients.

Recent study reported that GSTM1 null genotype was present in 52 % of lung cancer in Turkish patients [22] and in another study the percentage was 45.5% for the GSTM1 deletion in patients with LC and 48.1% in their control group among Brazilian population indicating that there is no influence for that polymorphism in the risk of LC [4].

The last finding was similar to our results as we found that there is no significant difference in GSTM1 null genotype between LC patients and control group suggesting that no association between GSTM1 polymorphism and lung cancer. Nazar-Stewart et al. [23] reported that effects of the polymorphism of the GSTM1 on lung cancer have been suspected due to loss of detoxification of carcinogens such as benzo[a]pyrene diolepoxide for 10 years of more. This is still unclear due to some reasons, e.g. low expression of GSTM1 in lung [24].

Modulation of DNA damage and mutation caused by polymorphisms in detoxification enzymes, including the GST, is a well-established risk factor for tobacco-related carcinogenesis and a similar change in cellular damage may be involved in the risk of vascular disease associated with tobacco smoking [25, 26]. In the current study, we tested interaction between GSTM1 genotype and smoking in lung cancer and control cases, it was found that smokers have high risk susceptibility for lung cancer either in GSTM1-positive or null genotype and that was similar to what is found in cases of coronary artery disease (CAD) as the smokers with GSTM1-positive genotype were an approximately 1.21-fold higher risk of CAD and it was slightly higher with GSTM1-null genotype compared to non-smokers with GSTM1-positive genotype [19].

Miller et al. [27] in a North American population showed an association between polymorphic GSTP1 gene and lung cancer. The patient' single nucleotide polymorphism (SNP) frequencies were 46, 42 and 12% for genotypes Ile/Ile, Ile/Val, Val/Val, respectively. Also, in another study who studied the effect of genetic polymorphism of six genes on lung cancer susceptibility, it was shown that among various genetic polymorphisms, only the allele distribution of the GSTP1 polymorphism was significantly different between cases and controls, i.e. the proportion of GSTP1-mutant, the Val allele was higher in cases than controls [24]. That was similar to our results as we found that there is significant overall association between GSTP1 [Ile.sup.105]Val polymorphism and lung cancer indicating that that GSTP1 polymorphism increases the risk of lung cancer susceptibility.

However, mechanism of how the presence of the GSTP1-Val allele increases risk for lung cancer is not clear, yet. A clear evidence of the GSTP1 involvement for lung cancer is the high localization of the GSTP1 in lung, compared to other GST-isozymes. Also GSTP1 is responsible for more than 90% of the GST activity within the adult human lung epithelial cell population [28] and the enzyme encoded by GSTP1 Val allele exhibits different activity, affinity and thermostability according to substrates [11]. In the evaluation of the effect of interaction of GSTP1 gene and smoking on lung cancer risk, GSTP1 ile/ile genotype was used as a reference and the genetic model (ile/val and val/val) was evaluated as a genetic polymorphism. It was found that carriers of Val allele have an increased risk of lung cancer in non-smokers and a higher significant risk in smokers and that may be due to genotype-phenotype interaction, as it was found by Watson et al. [13] that there is higher GST activity in lung tissue samples with GSTP1 Ile/Ile genotype than with GSTP1 Ile/Val and Val/Val genotypes.

Our results was in agreement to what found by Ritchie et al. [29] who reported that GSTP1-null mice exposed to benzo[a]pyrene, a common constituent of tobacco smoke, exhibited a marked increase in lung tumor incidence relative to wild-type mice (92% versus 29%) indicating that GSTP1 plays a key role in vivo in determining susceptibility to lung cancer following exposure to chemical carcinogens of the type commonly found in tobacco smoke.

Some studies reported the association of combined gene polymorphisms with LC risk. Jourenkova-Mironova et al. [30] reported an increased risk of LC associated with the combination of the GSTM1 null, GSTP1 Ile/Val plus Val/Val. Also, Kihara and Noda [31] reported a potential interaction between the GSTP1 and GSTM1 genes in a Japanese population of male smokers, in which a higher risk of LC was associated with the combination of the variant allele for GSTP1 and GSTM1 null genotype. Our results also showed that OR of lung cancer was particularly high for the subjects carrying deficient genotype for both GSTM1 and GSTP1, however these results are not in agreement with other study which showed that there is no correlation of the GSTP1 polymorphism and GSTM1 null genotype and the risk of lung cancer in a Brazilian population [4]. However, combined studies that include various genetic polymorphisms in various genes/enzymes are needed to clarify genetic etiology of lung cancer.

In conclusion, our finding may be an important contribution towards the identification of the role of genetic polymorphism of glutathione S-transferase interactions for cancer-risk. Our results suggest that GSTM1 null genotype has no influence in the risk of lung cancer in Egyptian patients however presence of GSTP1 Val allele increases risk for lung cancer especially among smokers. Also, we found that combination of GSTP1 and GSTM1 polymorphism increases the risk for lung cancer. Further studies including examination of other genotypes also involved either in metabolic activation or detoxification of carcinogens are anticipated to further improve our ability to find genetic factors contributing to individual lung cancer susceptibility.




[1.] Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (8):S4-66.

[2.] Vaissiere T, Hung RJ, Zaridze D, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009; 69: 243-252.

[3.] Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol. Biomark. Prev. 2003; 12:689-98.

[4.] Honma HN, De Capitani EM, Perroud Jr. MW , et al. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer. 2008; 61:152-162.

[5.] Minelli C, Granell R, Newson R, et al. Glutathione-S-transferase genes and asthma phenotypes: a Human Genome Epidemiology (HuGE) systematic review and meta-analysis including unpublished data. International Journal of Epidemiology 2010; doi:10.1093/ije/dyp337.

[6.] Stucker I, Hirvonen A, Waziers I, et al. Genetic polymorphism of glutathione S-transferase as modulators of lung cancer susceptibility. Carcinogenesis 2002; 23 (9): 1475-1481.

[7.] Hirvonen A. Polymorphism of xenobiotic-metabolizing enzymes and susceptibility to cancer. Enviro. Health Prespect. 1999; 107: 37-47.

[8.] Seidegard J and Pero RW. The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum. Genet. 1985; 69: 66-8.

[9.] Penn A and Snyder CA. 1, 3 Butadience, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Circulation 1996; 93: 552-7.

[10.] Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen--DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl. Cancer Inst. 1995; 87:902-7.

[11.] Kim SU, Lee KM, Park SK, et al. Genetic Polymorphism of Glutathione S-transferase P1 and Breast Cancer Risk. Journal of Biochemistry and Molecular Biology. 2004; 37 (5): 582-585.

[12.] Hayes JD and Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and contributions of the isoenzymes to cancer chemoprotection and drug resistance. Crit Ver Biochem Mol Biol. 1995; 30:445-600.

[13.] Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphism: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998; 19: 275-280.

[14.] Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol Chem 1997; 272: 10004-12.

[15.] Johansson AS, Stenberg G, Widersten M, Mannervik B. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol. 1998; 278:687-98.

[16.] Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl. Cancer Inst 2002; 94: 936-42.

[17.] Lima-Jr. MM, Oliveira MN, Granja F, Trindade AC, De Castro Santos LE, Ward LS. Lack of Association of GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1 Polymorphisms for Susceptibility and Outcome in Brazilian Prostate Cancer Patients. Folia Biological (Praha) 2008; 54: 102-108.

[18.] Medrano JF, Aasen E, Sharrow L. DNA extraction from nucleated red blood cells. Biotechniques 1990; 8(1):43.

[19.] Kim SJ, Kim MG, Kim KS, Song JS, Yim SV, Chung JH. Impact of glutathione S-transferase M1 and T1 gene polymorphisms on the smoking-related coronary artery disease. J Korean Med Sci. 2008; 23(3):365-72.

[20.] Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997; 6:733-43.

[21.] Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotypes of glutathione S-transferase theta. Carcinogenesis 1995; 16:1243-5.

[22.] Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y. The Association between Polymorphisms in Glutathione S-Transferase (GSTM1 and GSTT1) and Lung Cancer Outcome. Cancer Investigation 2006; 24:497-501.

[23.] Nazar-Stewart V, Motulsky AG, Eaton DL, et al. The glutathione-S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 1993; 53 (10): 2313-8.

[24.] Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer 2007; 57:135-142.

[25.] Wilson WH, Grant PJ, Kain K, Warner DP, Wild CP. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutathione S-transferase M1 . Biomarkers 2003; 8: 43-50.

[26.] Schneider J, Bernges U, Philipp M, Woitowitz HJ. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett. 2004;208(1):65-74.

[27.] Miller DP, Liu G, De Vivo I, et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 2002; 62(15): 2819-23.

[28.] Fryer AA, Hume R, Strange RC. The development of glutathione S-transferase and glutathione peroxidase activities in human lung. Biochim Biophys Acta 1986; 883:448-53.

[29.] Ritchie KJ, Henderson CJ, Wang XJ, et al. Glutathione Transferase P Plays a Critical Role in the Development of Lung Carcinogenesis following Exposure to Tobacco-Related Carcinogens and Urethane. Cancer Res 2007; 67 (19): 9248-9257.

[30.] Jourenkova-Mironova N, Wikman H, Bouchardy C, et al. Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking related lung cancer. Pharmacogenetics 1998; 8: 495-502.

[31.] Kihara M and Noda K. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Cancer Letter 1999; 137: 53-60.

Maggie M. Ramzy * (1), Mohei El-Din M. Solliman (2), Hany A. Abdel-Hafiz (3), Randa Salah (4)

(1) Biochemistry Department, Faculty of Medicine, Minia University, Egypt

(2) Division of Genetic Engineering and Biotechnology, National Research Center, Egypt

(3) Division of Endocrinology, School of Medicine, University of Colorado Denver, USA

(4) National Cancer Institute, Egypt

* Corresponding author; Email:

Correspondence concerning this article should be addressed to Maggie M. Ramzy, Faculty of Medicine, Minia University, Egypt. EMail: / Tel: (002)0101089090 / Fax: (002)0862342813

Paper publication: 20 February 2011
Table 1: Age, gender, tobacco, histology and stage characteristics of
the patients and control groups

 Patients Controls [chi P-value
 (n=48) (n=42) square]

 <60 years 30 (62.5) 35 (83.3) 4.8 0.028
 >60 years 18 (37.5) 7 (16.7)

 Male 32 (66.7) 27 (64.3) 0.04 0.83
 Female 16 (33.3) 15 (35.7)

 Yes 33 (68.75) 14 (33.3) 11.26 0. 001
 No 15 (31.25) 28 (66.7)

 Small cell carcinoma 6 (12.5)
 Squamous cell carcinoma 33 (68.75)
 adenocarcinoma 9 (18.75)

Stage (TNM)
 I +II 17 (35.4)
 III + IV 31 (64.6)

M 1
 +ve 33 (68.75) 28 (66.7) 0.045 0.8
 -ve 15 (31.25) 14 (33.3)

 lle/lle 9 (18.7) 28 (66.6) 24.7 0.0001
 lle/val 31 (64.6) 7 (16.7)
 val/val 8 (16.7) 7 (16.7)

 Present 15 (31.25) 7 (16.7) 2.6 0.1
 Absent 33 (68.75) 35 (83.3)

--All values in brackets are in percentage.

Table 2: Association between GSTM1 and GSTP1 and lung cancer risk

 Patients Controls OR (95% CI) p-value
 n=48 (%) n=42 (%)

 Yes 33 (68.75) 14 (33.3) 9.3 (2.6-33.2) 0.001
 No 15 (31.25) 28 (66.7)

M 1
 +ve 33 (68.75) 28 (66.7) 1.0 (reference) 0.33
 -ve 15 (31.25) 14 (33.3) 0.5 (0.1-2.01)

 lle/lle 9 (18.7) 28 (66.6) 1.0 (reference)
 lle/val 31 (64.6) 7 (16.7) 3.5 (1.01-12.5) 0.042
 val/val 8 (16.7) 7 (16.7) 0.4 (0.2-0.8) 0.27

 Present 15 (31.25) 7 (16.7) 5.06 (1.3-20.2) 0.02
 Absent 33 (68.75) 35 (83.3) 1.0 (reference)

Table 3: Interaction between GSTM1 genotype and smoking on lung
cancer and control

 Case Control OR (95% CI) P value
 n=48 (%) n=42 (%)

M1(+)/NS * 6 (12.5) 15(35.7)
M1(-)/NS 9 (18.75) 13(30.95) 0.5 (0.2-1.3) 0.2
M1(+)/S 27( 56.25) 13(30.95) 2.9 (1.2-6.8) 0.017
M1(-)/S 6(12.5) 1(2.4) 5.8 (0.7-50.7) 0.1

* Reference.

-M1 (+): GSTM1-positive genotype; M1 (-): GSTM1 null genotype; NS:
non-smoker; S: smoker; OR: odds ratio

Table 4: Interaction between GSTP1 genotype and smoking on lung
cancer and control

 Case Control OR (95% CI) P value
 n=48 (%) n=42 (%)

P(A)/NS * 2 (4.15) 21(50)
P (B)/NS 15(31.25) 7(16.7) 2.3 (0.8-6.3) 0.1
P(A)/S 7(14.6) 7(16.7) 0.9 (0.3-2.6) 0.8
P (B)/S 24(50) 7(16.7) 5 (1.8-13.4) 0.001

* Reference.

-P (A): GSTP1-Ile-Ile genotype; P (B): GSTP1 Ile-Val plus Val-Val
genotypes; NS: non-smoker; S: smoker; OR: odds ratio.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ramzy, Maggie M.; Solliman, Mohei El-Din M.; Abdel-Hafiz, Hany A.; Salah, Randa
Publication:International Journal of Collaborative Research on Internal Medicine & Public Health (IJCRIMPH)
Article Type:Report
Date:Jan 1, 2011
Previous Article:Factorial validity and internal consistency of Malaysian adapted depression anxiety stress scale--21 in an adolescent sample.
Next Article:Late ventricular potentials can be predicted from twelve-lead ECG in post-infarction heart failure.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters